| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Protalix BioTherapeutics, Inc. | VP, Research & Development | Common Stock | 35,115 | $49,512 | $1.41 | 15 Aug 2023 | By Trust |
| Protalix BioTherapeutics, Inc. | VP, Research & Development | Stock Options (Right to Buy) | 35,115 | 15 Aug 2023 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| PLX | Protalix BioTherapeutics, Inc. | 15 Aug 2023 | 2 | $0 | 4 | VP, Research & Development | 17 Aug 2023, 16:30 |
| PLX | Protalix BioTherapeutics, Inc. | 07 Sep 2022 | 1 | $0 | 4 | VP, Research & Development | 09 Sep 2022, 17:03 |